Loading
For a cancer already cured in 90% of young people, the goal is curing without the chemotherapy and radiation that cause heart disease and second cancers decades later.
Classical Hodgkin lymphoma is already cured in most young people, so the aim of this idea is to cure early-stage disease without the chemotherapy and radiotherapy that cause heart disease and second cancers decades later. Brentuximab vedotin plus nivolumab hits the Reed-Sternberg cell through CD30 and its immune shield through PD-1 and PD-L1, and the doublet has produced high complete response rates in relapsed disease and as frontline induction in older patients in the SGN35-015 cohort. The hypothesis is that PET- or ctDNA-adapted brentuximab-nivolumab with minimal or no chemotherapy achieves high progression-free survival in stage I to II disease with fewer late effects than ABVD-based therapy. AHOD2131, run by the Children's Oncology Group, is testing this at an early clinical stage.
Nivolumab, like pembrolizumab, is a standard for relapsed Hodgkin lymphoma after transplant, and the activity seen here led to its testing in first-line therapy (S1826).
One of the most cited trial reports Europe PMC returns for Brentuximab vedotin in Hodgkin lymphoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited trial reports Europe PMC returns for Brentuximab vedotin in Hodgkin lymphoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial, CheckMate 205: nivolumab for relapsed or refractory classical Hodgkin lymphoma after autologous transplant failure, extended follow-up, Hodgkin lymphoma, Nivolumab.
Shares AHOD2131 (COG / NCTN), Brentuximab vedotin, Hodgkin lymphoma, Nivolumab.
Shares PET-adapted (response-adapted) therapy, Brentuximab vedotin, Advanced-stage classical Hodgkin lymphoma (stage III to IV), Hodgkin lymphoma.
Shares AHOD2131 (COG / NCTN), Brentuximab vedotin, Advanced-stage classical Hodgkin lymphoma (stage III to IV), Hodgkin lymphoma.
Shares Brentuximab vedotin, Advanced-stage classical Hodgkin lymphoma (stage III to IV), Hodgkin lymphoma, Antibody-drug conjugate (ADC).
Shares Brentuximab vedotin, Advanced-stage classical Hodgkin lymphoma (stage III to IV), Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Hodgkin lymphoma.
Shares A radiotherapy-free cure for early Hodgkin lymphoma that actually holds, Brentuximab vedotin, Advanced-stage classical Hodgkin lymphoma (stage III to IV), Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting.
Shares Brentuximab vedotin, Advanced-stage classical Hodgkin lymphoma (stage III to IV), Hodgkin lymphoma.